Does This News From the FDA Make Eli Lilly a Buy for 2025?

Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market. Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name Mounjaro. But doctors have prescribed either one to patients trying to shed pounds, and both have become blockbusters.These drugs have helped the big pharma player report double-digit quarterly revenue growth. Demand has been so strong, that it earlier surpassed supply and pushed Lilly to increase its manufacturing capacity to keep up.The supply problem has been one of the biggest risks for Lilly. With the tirzepatide shortage, compounding pharmacies had the authorization to produce their own versions of the drug and sell them. This clearly limited Lilly's revenue opportunity.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool